The purpose of this research is to understand how TIMP (tissue inhibitor of metalloproteinases) accomplishes its anticarcinogenic action in immortal 3T3 cells. To do this, we propose to perform genetic surgery on the mouse cDNA sequence encoding murine TIMP, using recombinant DNA techniques, to make site-directed mutations in the """"""""mini-gene"""""""". The mutant TIMP proteins will be produced in E. coli and their ability to inhibit the known matrix metalloproteinases (MMPs) assessed. These studies will tell us which portions of the protein are important to interact with the MMPS, and they will yield penetrating insights into the differences in the active sites of the various MMPs (which exhibit different substrate specificities). our experiments will proceed along two parallel tracks, one (spec.
aim #3) concerned with understanding the details of TIMP structure, the other (spec.
aim #1) dealing with developing mutant TIMPS able to discriminate among the MMPS. The second specific aim is to make minigenes encoding TIMPS with inhibitory activity against selected MMPs and to transfect them, as part of an expression cassette, into tumorigenic, metastatic cells (both our TIMP down-modulated lines and appropriate human lines) to determine their ability to suppress the oncogenic phenotype. The significance of this research lies in the knowledge it will produce regarding how TIMP functions in vivo to suppress tumor development. Is an MMP a target, and if so, which one is it? A better understanding of the structure of TIMP and how it interacts with the MMPs will be of fundamental importance not only to cancer but also to diseases of the joints (arthritis) and connective tissue pathologies. Although direct evidence that TIMP has the properties of an """"""""anti-oncogene"""""""" in human cancers is lacking, it is hard to believe that it does not have a significant role in suppressing or hindering the development of a malignancy and moderating its invasiveness.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050183-02
Application #
3194510
Study Section
Special Emphasis Panel (SRC (52))
Project Start
1990-09-01
Project End
1995-08-31
Budget Start
1991-09-01
Budget End
1992-08-31
Support Year
2
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Rutgers University
Department
Type
Schools of Arts and Sciences
DUNS #
038633251
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Park, Jun Hyoung; Vithayathil, Sajna; Kumar, Santosh et al. (2016) Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep 14:2154-2165
Vadakkan, Tegy J; Landua, John D; Bu, Wen et al. (2014) Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer. Stem Cells Transl Med 3:857-66
Zhang, Xiaomei; Claerhout, Sofie; Prat, Aleix et al. (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73:4885-97
Iyer, Vandana; Klebba, Ina; McCready, Jessica et al. (2012) Estrogen promotes ER-negative tumor growth and angiogenesis through mobilization of bone marrow-derived monocytes. Cancer Res 72:2705-13
Creighton, Chad J; Sada, Yvonne H; Zhang, Yiqun et al. (2012) A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat 132:993-1000
Dave, Bhuvanesh; Migliaccio, Ilenia; Gutierrez, M Carolina et al. (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-73
Yang, Wei Tse; Lewis, Michael T; Hess, Kenneth et al. (2010) Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 119:305-14
Creighton, Chad J; Chang, Jenny C; Rosen, Jeffrey M (2010) Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia 15:253-60
Creighton, Chad J; Li, Xiaoxian; Landis, Melissa et al. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 106:13820-5
Zhang, Xiaomei; Harrington, Nikesha; Moraes, Ricardo C et al. (2009) Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat 115:505-21

Showing the most recent 10 out of 31 publications